Viral Vectors & Vaccines – Program Chairs:
Otto-Wilhelm Merten, PhD • Généthon
Amine A. Kamen, PhD • McGill University

Cellular Therapies – Program Chairs:
Martin A. Giedlin, PhD • Poseida Therapeutics, Inc.
Gary K. Lee, PhD • Sangamo Therapeutics, Inc.

Baculovirus Expression Technology – Program Chairs:
Manuel J.T. Carrondo, PhD • Instituto de Biologia Experimental e Tecnológica (iBET)
Clifton E. McPherson, PhD • Protein Sciences Corporation, A Sanofi Company

SUNDAY • MARCH 4, 2018

4:00 pm – 7:00 pm	**Welcome Reception and Registration** in the Granby Ballroom Foyer, Third Floor

MONDAY • MARCH 5, 2018

7:00 am – 8:00 am	**Registration and Breakfast** in the Granby Ballroom Foyer, Third Floor
8:00 am – 8:30 am	**Meeting Overview** in Momentum, Third Floor

	Viral Vectors & Vaccines Momentum, Third Floor View Speaker Abstracts & Bios	Cellular Therapies Fusion, Third Floor View Speaker Abstracts & Bios	Baculovirus Expression Technology Energy, Third Floor View Speaker Abstracts & Bios
8:30 am – 9:15 am	*OneBac rAAV Scale-Up Production Platform with Serotype-Specific Modulation of AAV Capsid Protein Stoichiometry* **Sergei Zolotukhin, PhD** University of Florida	*Successful Manufacturing of T-Cell Therapies: Challenges and Opportunities* **Cenk Sumen, PhD** Hitachi Chemical Advanced Therapeutics Solutions, LLC	*The Complete Genome Sequences of Two Trichoplusia ni Cell Lines* **Dominic Esposito, PhD** Frederick National Laboratory for Cancer Research and **Yu Fu** University of Massachusetts Medical School
9:15 am – 10:00 am	*Biological Activity of Additional AAV Subpopulation in AAV Gene Therapy Product* **Marian Bendik** Shire	*Cell Therapy: Islet Isolation and Transplant Quality Control Release Considerations* **Lisa Stehno-Bittel, PhD** Likarda, LLC	*Cervarix Vaccine: From Baculovirus Technology to the First Human BEVS-Based Vaccine* **Isabelle Knott, PhD** GlaxoSmithKline Biologicals
10:00 am – 10:30 am	**Morning Break in the Exhibit Area**		
10:30 am – 11:00 am	**Technology Workshop** *Consideration for Biosafety Testing of Viral Vectors and Vaccines* SGS Vitrology	**Technology Workshop** *Design of Experiments and Multivariate Data Analysis in the Future of Cell Therapy and Regenerative Medicine* Sartorius Stedim North America Inc.	**Technology Workshop** *A Chemically-Defined Baculovirus-Based Expression System for Enhanced Protein Production in Sf9 Cells* Thermo Fisher Scientific
11:00 am – 11:30 am	**Technology Workshop** *Scaling Up and Industrializing the Production of Viral Vectors and Cells for Therapeutic Use* Pall Life Sciences	**Technology Workshop** *Development of Commercially Viable Manufacturing Processes for Cell and Gene Therapy Applications* Lonza	**Technology Workshop** *Laser Force Cytology: A Novel Technology for Rapid Quantification of Viral Infectivity and Label-Free Cellular Analysis* LumaCyte
11:30 am – 12:00 noon	**Technology Workshop** *Industrial Platform Purification of AAV* BIA Separations	**Technology Workshop** *Gibco™ LV-MAX™ Lentiviral Production System for Cell Therapy Applications* Thermo Fisher Scientific	
12:00 noon – 1:30 pm	**Lunch in the Exhibit Area (Poster Session from 1:00 – 1:30 pm)**		
1:30 pm – 2:15 pm	*The Development and Intensification of a Lentiviral Vector Manufacturing Process Using Stable Cell Lines* **Lesley Chan, PhD** bluebird bio Inc.	*CAR T-Cells with Non-Viral Gene-Editing Technology* **David L. Hermanson** Poseida Therapeutics, Inc.	*Towards Routine Manufacturing of Gene Therapy Drugs – Requirements for Further Improvements – Example: AAV* **Otto-Wilhelm Merten, PhD** Généthon
2:15 pm – 3:00 pm	*Viral Vector Manufacturing: Challenges and Solutions* **Hanna P. Lesch, PhD** FinVector Vision Therapies OY	*Enhancing CAR T-Cell Specificity for Malignancy and Maintaining Durable Persistence in Solid Tumor Models* **Avery D. Posey Jr., PhD** University of Pennsylvania	*Enabling Access to a Norovirus Virus-Like Particle-Based Vaccine Through Advanced Manufacturing Process Design* **Scot Shepard** Takeda Pharmaceuticals U.S.A., Inc.
3:00 pm – 3:30 pm	**Afternoon Break in the Exhibit Area**		
3:30 pm – 4:15 pm	*Characterization of Stability-Indicating Assays for Viral Vectors* **Lawrence C. Thompson, PhD** Pfizer, Inc.	*Metabolomics: Enabling Understanding and Optimization of Bioprocesses and Immunotherapies* **Kendra Hightower, PhD** Metabolon, Inc.	*Bioprocess Engineering of Insect Cells for Pseudotyped VLP Expression and Optimization* **António M. Roldao, PhD** Instituto de Biologia Experimental e Tecnológica
4:15 pm – 5:00 pm	*Analytical Strategies on Quantification of Adeno-Associated Virus (AAV) Empty Capsids to Support Process Development* **Xiaohui Lu, PhD** Biogen	*Achieving High Quality Cell-Based Measurement: Application to Process Controls and Potency Assays* **John T. Elliott** National Institute of Standards & Technology	*Tweaking Baculovirus Expression Vectors to Stabilize Transgenes and Polish Enveloped VLP Vaccines* **Gorben P. Pijlman, PhD** Wageningen University
5:00 pm – 6:00 pm	**Plenary Session** in Momentum, Third Floor: **Air Handling for Viral Vector Suites** **Christian D. Lynch • FDA CBER**, **Mark F. Witcher, PhD • NNE**, and **Kim L. Nelson, PhD • CRB**		
6:00 pm – 8:00 pm	**Reception in the Exhibit Area**		

	Viral Vectors & Vaccines Momentum, Third Floor	Cellular Therapies Fusion, Third Floor	Baculovirus Expression Technology Energy, Third Floor
7:30 am – 8:30 am	**Breakfast in the Exhibit Area**		
8:30 am – 9:15 am	*Analytical Issues for AAV Gene Therapy Products: Vector Genome Titration and Full/Empty Viral Particles Quantification* **Christine Le Bec, PhD** Généthon	*High Throughput Identification of Naturally-Occurring T-Cell Receptors with Therapeutic Potential Against Tumor-Associated, Viral, and Neoantigens* **Adria Carbo, PhD** Adaptive Biotechnologies	*Simplifying Membrane Protein Purification: Introducing a Fluorescent BEVS Protein System that Enhances Protein Production and Greatly Simplifies Detergent Screening* **Kendra Steele, PhD** ParaTechs Corporation
9:15 am – 10:00 am	*Many Ways Lead to Rome for Assessing the Genetic Stability of a Viral Vector* **Pepijn Burgers, PhD** Janssen Vaccines & Prevention B.V.	*Improving the Preservation of T-Cells* **Chia-Hsing Pi** University of Minnesota	*Adventitious Viruses Contaminating Insect Cell Lines* **Christoph Geisler, PhD** GlycoBac LLC
10:00 am – 10:30 am	**Morning Break in the Exhibit Area**		
10:30 am – 11:15 am	*Novel Purification Process to Obtain Pure AAV Vectors of 1e+16 vg in a Single Run of Conventional Ultracentrifuge* **Haifeng Chen, PhD** Virovek, Inc.	*T-Cell Activation Co-Stimulatory Ligands on a Dissolvable Substrate to Modulate T-Cell Output* **Sean H. Kevlahan, PhD** Quad Technologies	*Regulatory Updates and Using Virus-Like Particles to Inform Norovirus Vaccine Design* **Robin Levis, PhD** and **Gabriel I. Parra, PhD** FDA CBER
11:15 am – 12:00 noon	*Scalable Lentiviral Vector Production Using Stable HEK293 Suspension Cells* **Aziza P. Manceur, PhD** National Research Council Canada	*Analytical Considerations Associated With the Development of Novel Modalities* **Sunetra Biswas, PhD** Kite, A Gilead Company	*Comparative Transcriptome Analysis of AcMNPV Infection in the Midgut of Host Insect Trichoplusia ni, and in a T. ni Cell Line* **Gary W. Blissard, PhD** Boyce Thompson Institute
12:00 noon – 12:45 pm	*Testing Approaches for Viral Vectors Used in Gene Therapy: Novel Methods and Regulatory Expectations* **Leyla Diaz, PhD** MilliporeSigma BioReliance® Services		
12:45 pm – 2:00 pm	**Lentivirus Reference Standard Working Group Meeting** in Energy, Third Floor		
12:45 pm – 6:00 pm	Free Afternoon with Recommended Group Activities: **River Cruise on the Victory Rover • Admission to Nauticus and the Battleship Wisconsin • Guided Historical Walking Tour • Guided Engine Room Tour**		
6:00 pm – 9:00 pm	**Psychedelic Banquet at Half Moone featuring BJ Griffin & the Galaxy Groove**		

WEDNESDAY • MARCH 7, 2018

7:30 am – 8:30 am	**Breakfast in the Exhibit Area**		
8:30 am – 9:15 am	*Challenges in Process Development and Industrialization for Live Virus Vaccine: Flavivirus Experience Using a Vero Cell Line* **Etienne Boutry** Sanofi Pasteur SA	*Chemically-Defined Culture Media for Advancing Cell Therapy Technology* **Jessie H.T. Ni, PhD** Irvine Scientific	*Control Using BEVS: From Promoters to CRISPR* **Marc G. Aucoin, PhD** University of Waterloo
9:15 am – 10:00 am	*Large-Scale Manufacturing of Clinical-Grade rAAV in an Academic Setting: How Efficacy, Versatility, Space, and Cost Drive Process and Development Toward Sustainable Methods* **Nathalie A. Clément, PhD** University of Florida	*The Role of Leukapheresis and Elutriation in Cell Immunotherapy Manufacturing* **Joseph M. Roig** Terumo BCT	*HER2 Cancer Vaccine Optimization by Combining Drosophila S2 Insect Cell Manufacturing with a Novel VLP-Display Technology* **Willem "Wian" A. de Jongh, PhD** ExpreS2ion Biotechnologies
10:00 am – 10:30 am	**Morning Break in the Exhibit Area**		
10:30 am – 11:15 am	*Novel Stable Lentiviral Vector Producer Cells: Overcoming Viral Vector Cytotoxicity* **Ana Sofia Coroadinha, PhD** Instituto de Biologia Experimental e Tecnológica	*Engineered Pluripotent Cell-Derived NK Cells as a Cornerstone Approach for Off-the-Shelf Cancer Immunotherapy* **Bahram "Bob" Valamehr, PhD** Fate Therapeutics, Inc.	*Progress on the Genome of the Spodoptera frugiperda Sf9 Cell Line* **Arifa S. Khan, PhD** FDA CBER
11:15 am – 12:00 noon	*Retroviral and Lentiviral Production in Disposable Bioreactor: Development and Scaling Up of Upstream and Downstream Process Steps* **Francesca Bellintani** MolMed S.p.A.	*Optimizing the CAR T-Cell Supply Chain* **Kimberly Lounds-Foster** Celgene Corporation	*rAAV Vector Development and Large-Scale Manufacturing Using BEVS Technology* **Jacek Lubelski, PhD** uniQure N.V.
12:00 noon – 1:30 pm	**Lunch in the Exhibit Area (Poster Session from 1:00 – 1:30 pm)**		
1:30 pm – 2:15 pm	*The Use of Automation in the Development of Lentiviral Vector Packaging and Producer Cell Lines* **Helen Maunder, PhD** Oxford BioMedica plc	*Automated, Closed System Manufacturing of CAR T-Cells* **Jon Ellis** Thermogenesis Corp.	*PEI-Mediated Transient Transfection of Insect Cells for the Expression of Recombinant Proteins in Stirred-Tank Bioreactors* **Christopher W. Kemp, PhD** Kempbio, Inc.
2:15 pm – 3:00 pm	*CAP-GT, a Platform Addressing the Production Challenge* **Nicole Faust, PhD** Cevec Pharmaceuticals GmbH	*Regulatory Approval of Modern Gene-Based Cancer Immunotherapies — CAR T-Cells — A Product Perspective* **Xiaobin "Victor" Lu, PhD** FDA CBER	*Biochemical and Biophysical Characterization of Adeno-Associated Viruses Produced by Triple Transfection in HEK293 Cells and with Insect Cells/Baculovirus Expression System* **Eric Horowitz, PhD** Voyager Therapeutics
3:00 pm – 3:30 pm	**Afternoon Break in the Exhibit Area**		
3:30 pm – 4:15 pm	*Pushing the Boundaries of Adeno-Associated Virus Characterization for Enhanced Product and Process Understanding* **Thomas Wesley Powers** Pfizer, Inc.	*Integrated, Closed System PAT Analytics for Advanced Auto Feedback Control of Critical Process Parameters – Reactive Analytics* **Dan Kopec** Sartorius Stedim Biotech	*Performance of High Cell Density Fed-Batch Process at Small- and Large-Scales* **Jamal Meghrous, PhD** Protein Sciences Corporation, A Sanofi Company
4:15 pm – 5:00 pm	*A Suspension Vero Cell Line for Production of Viral Vaccines and Viral Therapeutics* **Steven E. Pincus, PhD** FUJIFILM Diosynth Biotechnologies Texas, LLC	*Tumor Infiltrating Lymphocytes: Streamlining Manufacturing for Multi-Center Clinical Trials and Commercialization* **Linda L. Kelley, PhD** H. Lee Moffitt Cancer Center & Research Institute	*HepE Viral Nanoparticle (HEVNP): A Multifunctional Platform for Oral Delivery* **Chun C. Chen, PhD** Astrid Pharma
5:00 pm	**Meeting Adjourns**		

Due to circumstances beyond the control of meeting organizers, this program is subject to change without notice. REV 03/05/18